STOCK TITAN

Keros Therapeutics, Inc. - $KROS STOCK NEWS

Welcome to our dedicated page for Keros Therapeutics news (Ticker: $KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Keros Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Keros Therapeutics's position in the market.

Rhea-AI Summary
Keros Therapeutics, a clinical-stage biopharmaceutical company, provided a business update and reported financial results for Q3 2023. The company made progress in its pipeline, including advancing two Phase 2 clinical trials for KER-050 and progressing the TROPOS Phase 2 trial for KER-012. Keros also deprioritized the KER-047 program. In terms of financials, the company reported a net loss of $39.4 million in Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
-
Rhea-AI Summary
Keros Therapeutics, Inc. announced that it will be presenting five abstracts from its hematology program at the 65th American Society of Hematology Annual Meeting. The abstracts will include additional results from its ongoing Phase 2 clinical trials of KER-050 in patients with myelodysplastic syndrome (MDS) and myelofibrosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
conferences
-
Rhea-AI Summary
Keros Therapeutics announces positive preclinical results for KER-065 in treating Duchenne muscular dystrophy (DMD) and prednisolone-treated mice
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Keros Therapeutics, Inc. announces CEO's participation in upcoming healthcare conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.61%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
conferences
Keros Therapeutics, Inc.

Nasdaq:KROS

KROS Rankings

KROS Stock Data

2.18B
30.79M
6.38%
88.88%
5.84%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
LEXINGTON

About KROS

keros therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. the company's lead protein therapeutic product candidate is ker-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or mds, and in patients with myelofibrosis. it is also developing small molecule product candidate ker-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or fop, and is currently in a phase 1 clinical trial; and ker-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or pah. the company was founded i